Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer

IntroductionTamoxifen is the most widely prescribed anti-estrogen treatment for patients with estrogen receptor (ER)-positive breast cancer. However, there is still a need for biomarkers that reliably predict endocrine sensitivity in breast cancers and these may well be expressed in a dynamic manner.MethodsIn this study we assessed gene expression changes at multiple time points (days 1, 2, 4, 7, 14) after tamoxifen treatment in the ER-positive ZR-75-1 xenograft model that displays significant changes in apoptosis, proliferation and angiogenesis within 2 days of therapy.ResultsHierarchical clustering identified six time-related gene expression patterns, which separated into three groups: two with early/transient responses, two with continuous/late responses and two with variable response patterns. The early/transient response represented reductions in many genes that are involved in cell cycle and proliferation (e.g. BUB1B, CCNA2, CDKN3, MKI67, UBE2C), whereas the continuous/late changed genes represented the more classical estrogen response genes (e.g. TFF1, TFF3, IGFBP5). Genes and the proteins they encode were confirmed to have similar temporal patterns of expression in vitro and in vivo and correlated with reduction in tumour volume in primary breast cancer. The profiles of genes that were most differentially expressed on days 2, 4 and 7 following treatment were able to predict prognosis, whereas those most changed on days 1 and 14 were not, in four tamoxifen treated datasets representing a total of 404 patients.ConclusionsBoth early/transient/proliferation response genes and continuous/late/estrogen-response genes are able to predict prognosis of primary breast tumours in a dynamic manner. Temporal expression of therapy-response genes is clearly an important factor in characterising the response to endocrine therapy in breast tumours which has significant implications for the timing of biopsies in neoadjuvant biomarker studies.

[1]  J. Haerting,et al.  Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.

[2]  Vladimir B. Bajic,et al.  Dragon ERE Finder version 2: a tool for accurate detection and analysis of estrogen response elements in vertebrate genomes , 2003, Nucleic Acids Res..

[3]  A. Ashworth,et al.  Molecular response to aromatase inhibitor treatment in primary breast cancer , 2007, Breast Cancer Research.

[4]  T. Yamori,et al.  Development of cDNA microarray for expression profiling of estrogen-responsive genes. , 2002, Journal of molecular endocrinology.

[5]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[6]  A. Dunker,et al.  Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data , 2008, BMC Medical Genomics.

[7]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Macleod,et al.  Effects of estrogen on global gene expression: identification of novel targets of estrogen action. , 2000, Cancer research.

[9]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Gianluca Bontempi,et al.  Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen , 2008, BMC Genomics.

[12]  C. Nguyen,et al.  A candidate molecular signature associated with tamoxifen failure in primary breast cancer , 2008, Breast Cancer Research.

[13]  D. Cameron,et al.  The relative importance of proliferation and cell death in breast cancer growth and response to tamoxifen. , 2001, European journal of cancer.

[14]  T. Toyama,et al.  Prognostic significance of insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5 expression in breast cancer. , 2007, Japanese journal of clinical oncology.

[15]  R. Tibshirani,et al.  Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data , 2004, PLoS biology.

[16]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[17]  Robin L. Jones,et al.  The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer , 2009, Breast Cancer Research and Treatment.

[18]  Terry Speed,et al.  Normalization of cDNA microarray data. , 2003, Methods.

[19]  Lucia Altucci,et al.  A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. , 2004, Journal of molecular endocrinology.

[20]  J. Bartlett,et al.  Approaches towards expression profiling the response to treatment , 2008, Breast Cancer Research.

[21]  P F Sharp,et al.  Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A Howell,et al.  Effects of oestrogen on gene expression in epithelium and stroma of normal human breast tissue. , 2006, Endocrine-related cancer.

[23]  John F Smyth,et al.  Insulin-like Growth Factor Binding Proteins IGFBP3, IGFBP4, and IGFBP5 Predict Endocrine Responsiveness in Patients with Ovarian Cancer , 2007, Clinical Cancer Research.

[24]  K. Coser,et al.  Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[26]  D. Cameron,et al.  Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression , 1997, Breast Cancer Research and Treatment.

[27]  G. Hampton,et al.  Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole , 2007, Pharmacogenetics and genomics.

[28]  D. Cameron,et al.  Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. , 2007, Gynecologic oncology.

[29]  Claudia Angelini,et al.  Time-course analysis of genome-wide gene expression data from hormone-responsive human breast cancer cells , 2008, BMC Bioinformatics.

[30]  J. Dixon,et al.  Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer , 2010, Breast Cancer Research and Treatment.

[31]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[32]  Dennis B. Troup,et al.  NCBI GEO: mining millions of expression profiles—database and tools , 2004, Nucleic Acids Res..

[33]  Sven Bilke,et al.  The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles. , 2003, Cancer research.

[34]  C Sotiriou,et al.  Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  Arul M Chinnaiyan,et al.  Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors , 2006, Genome Biology.

[36]  M. Parker,et al.  Identification of novel oestrogen receptor target genes in human ZR75-1 breast cancer cells by expression profiling. , 2001, Journal of molecular endocrinology.

[37]  Yudong D. He,et al.  A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. , 2005, Cancer research.

[38]  [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer]. , 2007, Ai zheng = Aizheng = Chinese journal of cancer.

[39]  T. Speed,et al.  Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer , 2009, BMC Medical Genomics.

[40]  J. Diffley,et al.  Uninterrupted MCM2-7 function required for DNA replication fork progression. , 2000, Science.

[41]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[42]  Jingqin Luo,et al.  Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.

[43]  Clifford A. Meyer,et al.  Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.

[44]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[45]  K. Horwitz,et al.  Estradiol regulates different genes in human breast tumor xenografts compared with the identical cells in culture. , 2006, Endocrinology.

[46]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[47]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[48]  C. Sotiriou,et al.  Genomic grade index is associated with response to chemotherapy in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Weigel,et al.  PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. , 2000, Cancer research.

[50]  Margaret Gardiner-Garden,et al.  Identification of Functional Networks of Estrogen- and c-Myc-Responsive Genes and Their Relationship to Response to Tamoxifen Therapy in Breast Cancer , 2008, PloS one.

[51]  D. Cameron,et al.  Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. , 2000, European journal of cancer.

[52]  Tanja Cufer,et al.  The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy , 2009, Breast Cancer Research and Treatment.